Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 4Thyroid Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Multiple Myeloma 2Lymphoma 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioma 2Endometrial Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Solid Tumors 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neurofibromatosis 1 1Neoplasms 1Lymphatic Metastasis 1Klatskin Tumor 1

Interventions

binimetinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eye Neoplasms × binimetinib × 90 days × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡